Development of Vaccinia Virus as an Expression Vector

痘苗病毒表达载体的开发

• 批准号: 6506802
• 负责人: BERNARD MOSS
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6506802
• 关键词: biotechnology; gene expression; laboratory mouse; nucleic acid sequence; polymerase chain reaction; recombinant virus; transfection /expression vector; vaccine development; vaccinia virus; vector vaccine; virus genetics

The cytoplasmic site of gene expression and use of virally encoded enzymes are distinguishing features of vaccinia virus and other poxvirus vectors that contribute to their consistent ability to express genes derived from a variety of prokaryotic, eukaryotic and viral sources. This feature, together with their ability to stably integrate and package large amounts of additional DNA, and broad host range, account for their general use as a research tool and for synthesis of recombinant proteins in mammalian cells. Recombinant vaccinia viruses are also being tested as live vaccines. During the past year, we continued to evaluate the highly attenuated modified vaccinia virus Ankara (MVA) strain as a safe vector in the laboratory and as a vector for candidate vaccines against infectious diseases and cancers

基因表达的细胞质位点和病毒编码的酶的使用是牛痘病毒和其他痘病毒载体的区别特征，这有助于它们表达源自各种原核、真核和病毒来源的基因的一致能力。这一特征，连同它们稳定整合和包装大量额外DNA的能力，以及广泛的宿主范围，解释了它们作为研究工具和在哺乳动物细胞中合成重组蛋白的一般用途。重组牛痘病毒也正在作为活疫苗进行测试。在过去的一年中，我们继续评估高度减毒的改良安卡拉牛痘病毒（MVA）株作为实验室安全载体以及作为预防传染病和癌症的候选疫苗的载体